Trial reportJournal of pain research2026
Effects of Transverse Abdominis Plane Block with Ropivacaine-Hydromorphone versus. Ropivacaine in Cesarean Section: A Randomized Controlled Trial.
Trial report in Journal of pain research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To compare the efficacy and safety of ultrasound-guided transverse abdominis plane block (TAPB) with ropivacaine combined with hydromorphone versus ropivacaine alone for postoperative analgesia in parturients undergoing cesarean section. Methods: A randomized controlled trial was conducted with 90 eligible parturients scheduled for elective cesarean section. They were randomly assigned to the experimental group (Group R+H, n=45) receiving TAPB with 0.25% ropivacaine plus 0.2 mg hydromorphone (20 mL per side), and the control group (Group R, n=45) receiving TAPB with 0.25% ropivacaine. The primary outcome was the time to first rescue analgesia. Secondary outcomes included serum prolactin (PRL) levels, pain intensity, patient-controlled analgesia (PCA) usage, postoperative recovery indicators, adverse reactions, and patient satisfaction. Results: The time to first PCA use was significantly longer in Group R+H than in Group R (7.32±4.80 h vs. 3.49±1.74 h, Conclusion: Ultrasound-guided TAPB with ropivacaine combined with hydromorphone provides superior early postoperative analgesia, reduces rescue analgesic requirements, and improves patient satisfaction in parturients undergoing cesarean section. It does not affect perioperative PRL levels or postoperative recovery, nor does it increase adverse events, making it a safe and effective analgesic strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.